Correct Capital Wealth Management Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Correct Capital Wealth Management bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,595 shares of the medical equipment provider's stock, valued at approximately $644,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Avantax Advisory Services Inc. grew its stake in Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after purchasing an additional 132 shares in the last quarter. Foundry Partners LLC raised its position in shares of Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after acquiring an additional 133 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Lantheus by 2.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after acquiring an additional 139 shares in the last quarter. Moody National Bank Trust Division raised its position in shares of Lantheus by 1.0% during the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after acquiring an additional 141 shares in the last quarter. Finally, Aurora Investment Counsel increased its stake in Lantheus by 0.8% during the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after purchasing an additional 146 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company's stock.

Lantheus Stock Performance

NASDAQ:LNTH traded down $2.46 during mid-day trading on Friday, hitting $81.37. The stock had a trading volume of 346,421 shares, compared to its average volume of 999,541. The stock has a market capitalization of $5.63 billion, a price-to-earnings ratio of 23.12 and a beta of 0.12. The company has a 50 day simple moving average of $80.81 and a 200-day simple moving average of $90.01. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the previous year, the business posted $1.69 EPS. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on LNTH. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus currently has a consensus rating of "Buy" and an average price target of $130.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.